Insider · CIK 0001134657
Luke Evnin
ownerdirectorother
Files at TRDA (Entrada Therapeutics, Inc.), HOWL (Werewolf Therapeutics, Inc.). First filing Apr 30, 2025, latest Jul 8, 2026.
Luke Evnin files SEC Form 4 as 10% owner and director at HOWL (Werewolf Therapeutics, Inc.), and also at TRDA (Entrada Therapeutics, Inc.). Since Apr 30, 2025, Luke Evnin has reported 0 open-market buys worth $0 and 32 open-market sells worth $3.3M, the latest filed on Jul 8, 2026.
A track record needs three past buys with six months of prices behind them; Luke Evnin has 0, so none is measured yet.
The newest scored trade: sold $45k of HOWL on Jul 6, 2026, filed Jul 8, 2026, scored 21 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 31 sells worth $3.3M.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 32
$0 bought, $3.3M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
HOWL: Werewolf Therapeutics, Inc.
HOWLOct 9, 2026 · close 0.98
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Werewolf Therapeutics, Inc. | $45k 143,199 shares | -100% | +4% from low-85% from high | |
| 29Weak | Werewolf Therapeutics, Inc. | $47k 157,084 shares | -52% | 0% from low-86% from high | |
| 13Weak | Werewolf Therapeutics, Inc. | $28k 76,928 shares | -20% | 0% from low-83% from high | |
| 14Weak | Werewolf Therapeutics, Inc. | $43k 105,565 shares | -22% | +2% from low-80% from high | |
| 16Weak | Werewolf Therapeutics, Inc. | $64k 139,803 shares | -22% | +10% from low-79% from high | |
| 16Weak | Werewolf Therapeutics, Inc. | $66k 141,106 shares | -18% | +16% from low-78% from high | |
| 17Weak | Werewolf Therapeutics, Inc. | $87k 191,762 shares | -20% | 0% from low-81% from high | |
| 16Weak | Werewolf Therapeutics, Inc. | $76k 171,049 shares | -15% | 0% from low-77% from high | |
| 3Weak | Werewolf Therapeutics, Inc. | $24k 44,679 shares | -4% | +6% from low-73% from high | |
| 27Weak | Werewolf Therapeutics, Inc. | $280k 407,574 shares | -26% | +24% from low-69% from high | |
| 11Weak | Werewolf Therapeutics, Inc. | $64k 100,581 shares | -6% | +22% from low-69% from high | |
| 20Weak | Werewolf Therapeutics, Inc. | $198k 274,619 shares | -14% | +31% from low-67% from high | |
| 14Weak | Werewolf Therapeutics, Inc. | $155k 205,911 shares | -10% | +51% from low-62% from high | |
| 0Weak | Werewolf Therapeutics, Inc. | $21k 38,782 shares | -2% | 0% from low-75% from high | |
| 2Weak | Werewolf Therapeutics, Inc. | $62k 111,227 shares | -5% | 0% from low-74% from high | |
| 2Weak | Werewolf Therapeutics, Inc. | $54k 91,374 shares | -4% | +3% from low-71% from high | |
| 1Weak | Werewolf Therapeutics, Inc. | $46k 71,054 shares | -3% | +5% from low-71% from high | |
| 2Weak | Werewolf Therapeutics, Inc. | $48k 78,377 shares | -3% | 0% from low-72% from high | |
| 12Weak | Werewolf Therapeutics, Inc. | $185k 291,283 shares | -10% | +6% from low-69% from high | |
| 17Weak | Werewolf Therapeutics, Inc. | $52k 48,171 shares | -2% | - | |
| 19Weak | Werewolf Therapeutics, Inc. | $89k 82,971 shares | -3% | - | |
| 20Weak | Werewolf Therapeutics, Inc. | $95k 95,179 shares | -3% | - | |
| 20Weak | Werewolf Therapeutics, Inc. | $118k 128,185 shares | -4% | - | |
| 19Weak | Werewolf Therapeutics, Inc. | $88k 91,088 shares | -3% | - | |
| 20Weak | Werewolf Therapeutics, Inc. | $115k 125,576 shares | -4% | - | |
| 20Weak | Werewolf Therapeutics, Inc. | $95k 102,753 shares | -3% | - | |
| 21Weak | Werewolf Therapeutics, Inc. | $129k 134,553 shares | -4% | - | |
| 21Weak | Werewolf Therapeutics, Inc. | $155k 137,041 shares | -4% | - | |
| 22Weak | Werewolf Therapeutics, Inc. | $190k 155,885 shares | -4% | - | |
| 23Weak | Werewolf Therapeutics, Inc. | $251k 189,356 shares | -5% | - | |
| 24Weak | Werewolf Therapeutics, Inc. | $286k 177,145 shares | -4% | - | |
| 30Weak | Werewolf Therapeutics, Inc. | $2,546 2,425 shares | -0% | - |
Transactions
The newest 50 of 92 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 6, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -35,770 | $0.32 | $11k | 107,429 | Jul 8, 2026 |
| Jul 7, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -107,429 | $0.31 | $33k | 0 | Jul 8, 2026 |
| Jun 29, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -157,084 | $0.30 | $47k | 143,199 | Jun 29, 2026 |
| Jun 9, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -76,928 | $0.37 | $28k | 300,283 | Jun 10, 2026 |
| Jun 4, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -20,072 | $0.44 | $8,832 | 462,704 | Jun 8, 2026 |
| Jun 5, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -24,946 | $0.40 | $9,978 | 437,758 | Jun 8, 2026 |
| Jun 8, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -60,547 | $0.40 | $24k | 377,211 | Jun 8, 2026 |
| Jun 1, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -80,459 | $0.47 | $38k | 542,120 | Jun 3, 2026 |
| Jun 2, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -29,595 | $0.45 | $13k | 512,525 | Jun 3, 2026 |
| Jun 3, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -29,749 | $0.42 | $12k | 482,776 | Jun 3, 2026 |
| May 27, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -80,852 | $0.48 | $39k | 682,833 | May 29, 2026 |
| May 28, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -27,698 | $0.46 | $13k | 655,135 | May 29, 2026 |
| May 29, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -32,556 | $0.45 | $15k | 622,579 | May 29, 2026 |
| May 21, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -36,387 | $0.42 | $15k | 919,060 | May 26, 2026 |
| May 22, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -87,425 | $0.45 | $39k | 831,635 | May 26, 2026 |
| May 26, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -67,950 | $0.47 | $32k | 763,685 | May 26, 2026 |
| May 18, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -22,184 | $0.50 | $11k | 1,104,312 | May 20, 2026 |
| May 19, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -62,970 | $0.45 | $28k | 1,041,342 | May 20, 2026 |
| May 20, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -85,895 | $0.43 | $37k | 955,447 | May 20, 2026 |
| May 13, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -44,679 | $0.54 | $24k | 1,126,496 | May 13, 2026 |
| May 8, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -305,741 | $0.70 | $214k | 1,273,008 | May 12, 2026 |
| May 11, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -33,948 | $0.67 | $23k | 1,239,060 | May 12, 2026 |
| May 12, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -67,885 | $0.64 | $43k | 1,171,175 | May 12, 2026 |
| May 5, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -6,860 | $0.69 | $4,733 | 1,672,470 | May 7, 2026 |
| May 6, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -14,635 | $0.66 | $9,659 | 1,657,835 | May 7, 2026 |
| May 7, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -79,086 | $0.63 | $50k | 1,578,749 | May 7, 2026 |
| Apr 30, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -168,262 | $0.72 | $121k | 1,785,687 | May 4, 2026 |
| May 1, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -58,394 | $0.73 | $43k | 1,727,293 | May 4, 2026 |
| May 4, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -47,963 | $0.72 | $35k | 1,679,330 | May 4, 2026 |
| Apr 27, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -53,940 | $0.85 | $46k | 2,105,920 | Apr 29, 2026 |
| Apr 28, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -95,412 | $0.73 | $70k | 2,010,508 | Apr 29, 2026 |
| Apr 29, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -56,559 | $0.69 | $39k | 1,953,949 | Apr 29, 2026 |
| Jan 16, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -38,782 | $0.54 | $21k | 2,159,860 | Jan 20, 2026 |
| Jan 13, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -43,198 | $0.55 | $24k | 2,266,671 | Jan 15, 2026 |
| Jan 14, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -30,616 | $0.57 | $17k | 2,236,055 | Jan 15, 2026 |
| Jan 15, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -37,413 | $0.55 | $21k | 2,198,642 | Jan 15, 2026 |
| Jan 8, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -7,716 | $0.63 | $4,861 | 2,393,527 | Jan 12, 2026 |
| Jan 9, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -24,678 | $0.61 | $15k | 2,368,849 | Jan 12, 2026 |
| Jan 12, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -58,980 | $0.57 | $34k | 2,309,869 | Jan 12, 2026 |
| Jan 5, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -18,378 | $0.64 | $12k | 2,453,919 | Jan 7, 2026 |
| Jan 6, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -40,761 | $0.65 | $26k | 2,413,158 | Jan 7, 2026 |
| Jan 7, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -11,915 | $0.64 | $7,626 | 2,401,243 | Jan 7, 2026 |
| Dec 30, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -34,847 | $0.61 | $21k | 2,515,827 | Jan 2, 2026 |
| Dec 31, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -24,962 | $0.62 | $15k | 2,490,865 | Jan 2, 2026 |
| Jan 2, 2026 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -18,568 | $0.63 | $12k | 2,472,297 | Jan 2, 2026 |
| Dec 22, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -59,307 | $0.69 | $41k | 2,782,650 | Dec 29, 2025 |
| Dec 23, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -71,428 | $0.63 | $45k | 2,711,222 | Dec 29, 2025 |
| Dec 24, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -16,310 | $0.65 | $11k | 2,694,912 | Dec 29, 2025 |
| Dec 26, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -35,632 | $0.63 | $22k | 2,659,280 | Dec 29, 2025 |
| Dec 29, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -108,606 | $0.61 | $66k | 2,550,674 | Dec 29, 2025 |
50 of 92 rows shown.
Questions about Luke Evnin
Answered from the filings on this page, as of the latest one.
Is Luke Evnin buying or selling?
In the last 12 months Luke Evnin reported 0 open-market buys worth $0 and 31 open-market sells worth $3.3M on SEC Form 4; the latest was sold $45k of HOWL on Jul 6, 2026. Grants, option exercises and tax withholding are not counted.
How did Luke Evnin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Luke Evnin has 0.
Where does Luke Evnin file Form 4?
Luke Evnin has filed Form 4 at HOWL (Werewolf Therapeutics, Inc.); TRDA (Entrada Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.